Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers Pharmaceutical Investing
AbbVie's SKYRIZI® Receives Health Canada Approval as the First and Only Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease in Adults Pharmaceutical Investing
Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo Material Biotech Investing
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma Pharmaceutical Investing
Komo Plant Based Foods Reaches 400 Distribution Points with Addition of 11 Grocery Chains in Eastern Canada Biotech Investing
Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update Biotech Investing
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022 Market News
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022 Pharmaceutical Investing
Kite's Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Pharmaceutical Investing
AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire Pharmaceutical Investing
